Find the top 20 product net sales from continuing operations in 2024. Annual Sales of Tasigna reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Tasigna is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 … Novartis ' blockbuster drug Tasigna (nilotinib) is set to lose its exclusive status in the US in January 2024. A pivotal treatment for chronic myeloid leukemia (CML), with forecasted 2023 sales of $1.8 billion, Tasigna faces a significant sales decline. The global Tasigna market size was US$ 1590 million in 2024 and is forecast to a readjusted size of US$ 1088 million by 2031 with a CAGR of -5.4% during the forecast period 2025-2031. Tasigna's patent US 7,169,791 expired March 17, 2023, triggering generic competition [1]. The reimbursement environment also evolved, as Tasigna is reimbursed under Medicare Part D with average sales price-based payments post-patent expiry [2]. The Tasigna market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tasigna market comprehensively. The value covers manufacturer net sales of the originator Tasigna capsules, Azurity's Danziten nilotinib tartrate tablets and every generic nilotinib capsule sold for approved chronic myeloid leukemia indications in adults and children. Tasigna Market Dynamics 2026-2033 The Tasigna market landscape from 2026 to 2033 is characterized by a complex interplay of technological advancements, evolving regulatory frameworks, shifting patient demographics, and competitive innovation. As a targeted therapy primarily used in chronic myeloid leukemia (CML), the market dynamics are heavily influenced by the trajectory of precision … North America is the largest market for Tasigna Market, accounting for approximately 45% of global sales. The region's growth is driven by increasing cancer prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative therapies. Home – Pharma & Healthcare – Tasigna Market Analysis Tasigna Market Analysis 2026 The global Tasigna market size was USD 9715.5 million in 2024. Increased awareness and diagnosis of CML lead to higher treatment rates is expected to boost sales to USD 24610.92 million by 2031, with a Compound Annual Growth Rate (CAGR) of 14.20% from 2024 to 2031. Tasigna: A Comprehensive Insight into the Global Market Tasigna, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia, has gained significant market traction in recent years. This report provides an in-depth analysis of the global Tasigna market, including market trends, industry developments, key drivers, and future growth prospects. LPI is a top market research company certified by the industry. Its team of market analysts provides clients with high-quality customized market research and industry research reports. Compare prices and print coupons for Tasigna and other drugs at CVS, Walgreens, and other pharmacies. Prices start at $2,161.50 The US is one of the most important markets for Tasigna, as it contributed 39% of the drug's total historical revenue from 2008 to 2022. Global Info Research owns large basic databases and expert resourcesGlobal Info Research owns large basic databases and expert resources, focusing on Industry Analysis, management consulting, IPO consulting, database top industries services as well. Compare Tasigna 150 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for tasigna. Discounts up to 80% off the retail price. Access 100,000+ Professional Market Research Reports with 18+ Years Expertise. Get Customized Industry Analysis, IPO Consulting & Business Plans. Trusted by 60,000+ Clients in 5 Languages. Further, the study has identified and studied all the major players operating in the global tasigna drug market space and equated based on various parameters such as market revenue, annual sales volume, historical growth rate, and business strategies. Latest market research report on Tasigna. Complete industry analysis, market share, trends, CAGR, business opportunities, market size, forecast. Tasigna could replace use of Glivec, Novartis's second-biggest seller last year, with sales of $2.6 billion, in some situations, making it difficult to predict precise sales for each product … The report offers Tasigna Market Dynamics, Comprises Industry development drivers, challenges, opportunities, threats and limitations. A report also incorporates Cost Trend of products, Mergers & Acquisitions, Expansion, Crucial Suppliers of products, Concentration Rate of Steel Coupling Economy. Global Tasigna Market Research Report covers Market Effect Factors investigation chiefly included … Access 100,000+ Professional Market Research Reports with 18+ Years Expertise. Get Customized Industry Analysis, IPO Consulting & Business Plans. Trusted by 60,000+ Clients in 5 Languages. In a conference in September, Bloomberg says Herve Hoppenot, who oversees cancer drugs at Novartis, said the company wants Tasigna to "cannibalize" Gleevec until Gleevec is hit by generics. Compare Tasigna prices, print discount coupons, find manufacturer promotions, copay cards and patient assistance programs. Tasigna Market analysis indicates the market was valued at USD 1.31 Billion in 2025 and is anticipated to reach USD 3.13 Billion by 2035 with a CAGR of 9.1% over the forecast timeline. Compare Tasigna prices at 60,000+ US pharmacies. Get a free Rx.com coupon and save up to 90% on your prescription. Tasigna Market Latest Trends The Tasigna Market is increasingly influenced by personalized chronic myeloid leukemia management, with treatment decisions moving toward deeper integration of molecular response, safety assessment, patient characteristics, and previous therapy history. Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib's side-effect profile over Bristol's Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says. Chapter 3: Detailed analysis of Tasigna manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers … Novartis Patient Support™ Novartis Patient Support is a program designed to help your eligible patients start, stay, and save on TASIGNA. To learn more, call 1-800-282-7630. Tasigna copay assistance and nilotinib copay assistance programs help reduce or eliminate the out-of-pocket costs that patients pay for their medication. These programs are available through manufacturer-sponsored Tasigna copay cards, generic nilotinib copay cards, and independent patient assistance programs. The Global Tasigna Market was valued at USD 2.17 Billion in 2025 and is expected to reach USD 3.72 Billion by 2033, growing at a CAGR of 7.00% (2026-2033). Tasigna is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 … 13.1 Raw Material of Tasigna and Key Manufacturers 13.2 Manufacturing Costs Percentage of Tasigna 13.3 Tasigna Production Process 13.4 Tasigna Industrial Chain 14 Shipments by Distribution Channel 14.1 Sales Channel 14.1.1 Direct to End-User 14.1.2 Distributors 14.2 Tasigna Typical Distributors Tasigna is the brand name for nilotinib, an oral targeted cancer medication used in certain types of Philadelphia chromosome positive chronic myeloid leukemia. You can buy Tasigna online, view the current price, and choose the capsule strength and quantity that match the directions from your cancer care team. Commonly referenced strengths include Tasigna 150mg and Tasigna 200mg capsules, so … 6Wresearch actively monitors the United States (US) Tasigna Market and publishes its comprehensive annual report, highlighting emerging trends, growth drivers, revenue analysis, and forecast outlook. Novartis Site Directory This site is intended for US residents only Nilotinib, sold under the brand name Tasigna or Cavhanza among others, is an anti-cancer medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. [2][6] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. [2][6][7] It is taken by mouth. [2][7] Common side effects … Learn about Tasigna (nilotinib) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives.